

PROGRAM

08:30 REGISTRATION and welcome coffee
09:15 WELCOME
09:30 OPENING KEYNOTE - The identification of tumor-specific antigens
 by Dr. Thierry Boon, Emeritus Professor of the 'Université Catholique de Louvain' (UCL)

Research session

10:05 Recent developments of engineered poxviruses for oncolytic virotherapy, and anti-tumor vaccination

by **Dr. Eric Quéméneur**, Chief scientific officer (CSO) and Executive Vice-President (EVP) of Transgene S.A., France

10:30 COFFEE BREAK

11:00 The pursuit of tolerance: development of a cell-based therapy for multiple sclerosis by **Prof Nathalie Cools,** Laboratory for Experimental Hematology, UAntwerp

11:25 Pitch session

12:15 LUNCH & networking

Clinical session

13:45 Combination immunotherapy: dendritic cell therapy in combination with oncolytic virotherapy or immune checkpoint inhibition by Prof Bart Neyns, Medical Oncology, UZ Brussel

14:10 A new hope for acute leukemia: from stem cell transplantation to T-cell therapy by Prof Tessa Kerre, Head of Clinic Hematology, Ghent University Hospital, Senior clinical researcher, FWO

14:35 Pitch session

15:20 COFFEE BREAK

Closing session

15:50 CLOSING KEYNOTE - The Future of Immunotherapy: A 20-Year Perspective by Prof David C Wraith, Director Institute of Immunology and Immunotherapy, University of Birmingham (UK)

16:20 PANEL DISCUSSION with experts from the field16:50 CLOSING REMARKS17:00 Networking reception